Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), posed a significant global health challenge and still demands efforts to develop new therapies. In this study, we investigated the potential of biogenic silver nanoparticles (AgNPs) synthesized by the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Current Research in Biotechnology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590262825000061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859425529561088 |
|---|---|
| author | Marcus V.M.V. Amaral Cláudia B. Carraro Amanda C.C. Antoniêto Mariana N. Costa Thais F.C. Fraga-Silva Ualter G. Cipriano Rodrigo P.F. Abuná Tamara S. Rodrigues Ronaldo B. Martins Andreia M. Luzenti Glaucia R. Caruso Priscyla D. Marcato Vania L.D. Bonato Dario S. Zamboni Bergman M. Ribeiro Sônia N. Báo Joao S. da Silva Flávio P. Veras Roberto N. Silva |
| author_facet | Marcus V.M.V. Amaral Cláudia B. Carraro Amanda C.C. Antoniêto Mariana N. Costa Thais F.C. Fraga-Silva Ualter G. Cipriano Rodrigo P.F. Abuná Tamara S. Rodrigues Ronaldo B. Martins Andreia M. Luzenti Glaucia R. Caruso Priscyla D. Marcato Vania L.D. Bonato Dario S. Zamboni Bergman M. Ribeiro Sônia N. Báo Joao S. da Silva Flávio P. Veras Roberto N. Silva |
| author_sort | Marcus V.M.V. Amaral |
| collection | DOAJ |
| description | The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), posed a significant global health challenge and still demands efforts to develop new therapies. In this study, we investigated the potential of biogenic silver nanoparticles (AgNPs) synthesized by the fungus Trichoderma reesei to combat SARS-CoV-2 infection. In silico studies showed that AgNPs, ranging from 7 nm to 50 nm, have high affinity for spike protein from different variant of SARS-CoV-2. Our findings show that AgNPs effectively do not affect cell viability in Calu-3 cells, inhibit viral infection in Vero-E6 cells and progression of infection in vitro. Additionally, AgNPs impair caspase-1 activation, lactate dehydrogenase release and IL-1β production by human monocytes. Moreover, our study reveals that AgNPs treatment significantly alleviated acute lung injury induced by SARS-CoV-2 infection in Syrian hamsters. This suggests that AgNPs treatment effectively impairs viral replication or propagation within lung tissue, highlighting its potential as an antiviral agent against SARS-CoV-2. Further investigations are warranted to elucidate the underlying mechanisms of action of AgNPs and to assess their safety and efficacy in clinical settings. Nonetheless, our findings offer promising insights into the development of novel therapeutic strategies for combating COVID-19 and reducing its associated morbidity and mortality. |
| format | Article |
| id | doaj-art-be276f143ee8485ca1d9b6b95d74c987 |
| institution | Kabale University |
| issn | 2590-2628 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Biotechnology |
| spelling | doaj-art-be276f143ee8485ca1d9b6b95d74c9872025-02-11T04:35:27ZengElsevierCurrent Research in Biotechnology2590-26282025-01-019100277Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammationMarcus V.M.V. Amaral0Cláudia B. Carraro1Amanda C.C. Antoniêto2Mariana N. Costa3Thais F.C. Fraga-Silva4Ualter G. Cipriano5Rodrigo P.F. Abuná6Tamara S. Rodrigues7Ronaldo B. Martins8Andreia M. Luzenti9Glaucia R. Caruso10Priscyla D. Marcato11Vania L.D. Bonato12Dario S. Zamboni13Bergman M. Ribeiro14Sônia N. Báo15Joao S. da Silva16Flávio P. Veras17Roberto N. Silva18Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilInstitute of Biological and Health Sciences, Federal University of Alagoas, Maceio, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilFiocruz-Bi-Institutional Translational Medicine Project, Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Rua dos Técnicos, Ribeirão Preto, SP 14040-030, BrazilDepartment of Cell and Molecular Biology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, BrazilDepartment of Cell and Molecular Biology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, BrazilDepartment of Pharmaceutical Sciences, GNanoBio, School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, BrazilDepartment of Pharmaceutical Sciences, GNanoBio, School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, BrazilDepartment of Pharmaceutical Sciences, GNanoBio, School of Pharmaceutical Science of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Cell and Molecular Biology, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, BrazilLaboratory of Baculovirus, Cell Biology Department, University of Brasilia, Brasília, BrazilUniversity of Brasilia, Institute of Biological Sciences, Department of Cellular Biology, Microscopy and Myroanalysis Laboratory, Brasilia-DF, 70910-900, BrazilFiocruz-Bi-Institutional Translational Medicine Project, Department of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Rua dos Técnicos, Ribeirão Preto, SP 14040-030, BrazilDepartament of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, BrazilDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil; Corresponding author.The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), posed a significant global health challenge and still demands efforts to develop new therapies. In this study, we investigated the potential of biogenic silver nanoparticles (AgNPs) synthesized by the fungus Trichoderma reesei to combat SARS-CoV-2 infection. In silico studies showed that AgNPs, ranging from 7 nm to 50 nm, have high affinity for spike protein from different variant of SARS-CoV-2. Our findings show that AgNPs effectively do not affect cell viability in Calu-3 cells, inhibit viral infection in Vero-E6 cells and progression of infection in vitro. Additionally, AgNPs impair caspase-1 activation, lactate dehydrogenase release and IL-1β production by human monocytes. Moreover, our study reveals that AgNPs treatment significantly alleviated acute lung injury induced by SARS-CoV-2 infection in Syrian hamsters. This suggests that AgNPs treatment effectively impairs viral replication or propagation within lung tissue, highlighting its potential as an antiviral agent against SARS-CoV-2. Further investigations are warranted to elucidate the underlying mechanisms of action of AgNPs and to assess their safety and efficacy in clinical settings. Nonetheless, our findings offer promising insights into the development of novel therapeutic strategies for combating COVID-19 and reducing its associated morbidity and mortality.http://www.sciencedirect.com/science/article/pii/S2590262825000061COVID-19SARS-CoV-2Silver nanoparticlesTrichoderma reeseiInflammasome |
| spellingShingle | Marcus V.M.V. Amaral Cláudia B. Carraro Amanda C.C. Antoniêto Mariana N. Costa Thais F.C. Fraga-Silva Ualter G. Cipriano Rodrigo P.F. Abuná Tamara S. Rodrigues Ronaldo B. Martins Andreia M. Luzenti Glaucia R. Caruso Priscyla D. Marcato Vania L.D. Bonato Dario S. Zamboni Bergman M. Ribeiro Sônia N. Báo Joao S. da Silva Flávio P. Veras Roberto N. Silva Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation Current Research in Biotechnology COVID-19 SARS-CoV-2 Silver nanoparticles Trichoderma reesei Inflammasome |
| title | Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation |
| title_full | Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation |
| title_fullStr | Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation |
| title_full_unstemmed | Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation |
| title_short | Biogenic silver nanoparticles produced by Trichoderma reesei inhibit SARS-CoV-2 infection, reduce lung viral load and ameliorate acute pulmonary inflammation |
| title_sort | biogenic silver nanoparticles produced by trichoderma reesei inhibit sars cov 2 infection reduce lung viral load and ameliorate acute pulmonary inflammation |
| topic | COVID-19 SARS-CoV-2 Silver nanoparticles Trichoderma reesei Inflammasome |
| url | http://www.sciencedirect.com/science/article/pii/S2590262825000061 |
| work_keys_str_mv | AT marcusvmvamaral biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT claudiabcarraro biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT amandaccantonieto biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT marianancosta biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT thaisfcfragasilva biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT ualtergcipriano biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT rodrigopfabuna biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT tamarasrodrigues biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT ronaldobmartins biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT andreiamluzenti biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT glauciarcaruso biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT priscyladmarcato biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT vanialdbonato biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT darioszamboni biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT bergmanmribeiro biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT sonianbao biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT joaosdasilva biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT flaviopveras biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation AT robertonsilva biogenicsilvernanoparticlesproducedbytrichodermareeseiinhibitsarscov2infectionreducelungviralloadandameliorateacutepulmonaryinflammation |